Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2023-01-10 4:36 pm Sale | 13G | Aeglea BioTherapeutics, Inc. AGLE | INTEGRATED CORE STRATEGIES (US) LLC | 3,131,479 5.1% | -159,307 (-4.84%) | View |
| 2022-12-01 4:07 pm Purchase | 13G | Aeglea BioTherapeutics, Inc. AGLE | INTEGRATED CORE STRATEGIES (US) LLC | 3,290,786 5.3% | 3,290,786 (New Position) | View |
| 2022-06-09 3:20 pm Sale | 13G | Aeglea BioTherapeutics, Inc. AGLE | BlackRock Inc. BLK | 2,942,665 4.8% | -55,814 (-1.86%) | View |
| 2022-02-14 4:25 pm Sale | 13G | Aeglea BioTherapeutics, Inc. AGLE | Point72 Asset Management, L.P. | 56,098 0.1% | -2,873,689 (-98.09%) | View |
| 2022-02-14 08:01 am Purchase | 13G | Aeglea BioTherapeutics, Inc. AGLE | Nantahala Capital Management, LLC | 2,813,560 5.7% | 399,558 (+16.55%) | View |
| 2022-02-14 06:40 am Purchase | 13G | Aeglea BioTherapeutics, Inc. AGLE | BCLS II Equity Opportunities, LP | 2,847,689 5.8% | 147,689 (+5.47%) | View |
| 2022-02-11 4:12 pm Sale | 13G | Aeglea BioTherapeutics, Inc. AGLE | ORBIMED ADVISORS LLC | 3,956,124 7.9% | -1,059,400 (-21.12%) | View |
| 2022-02-10 5:03 pm Purchase | 13D | Aeglea BioTherapeutics, Inc. AGLE | BAKER BROS. ADVISORS LP | 5,044,478 9.9% | 143,288 (+2.92%) | View |
| 2022-02-10 4:13 pm Sale | 13G | Aeglea BioTherapeutics, Inc. AGLE | ELI LILLY & Co LLY | 1,526,516 3.1% | -1,042,027 (-40.57%) | View |
| 2022-02-10 11:14 am Purchase | 13G | Aeglea BioTherapeutics, Inc. AGLE | PICTET ASSET MANAGEMENT SA | 2,468,129 5% | 2,468,129 (New Position) | View |
| 2022-02-10 09:01 am Sale | 13G | Aeglea BioTherapeutics, Inc. AGLE | ADAGE CAPITAL PARTNERS GP, L.L.C. | 1,000,000 2.03% | -1,992,000 (-66.58%) | View |
| 2022-02-03 4:41 pm Sale | 13G | Aeglea BioTherapeutics, Inc. AGLE | BlackRock Inc. BLK | 2,998,479 6.1% | -241,496 (-7.45%) | View |
| 2021-12-16 4:32 pm Purchase | 13G | Aeglea BioTherapeutics, Inc. AGLE | SUVRETTA CAPITAL MANAGEMENT, LLC | 2,571,000 5.2% | 2,571,000 (New Position) | View |
| 2021-03-19 4:07 pm Purchase | 13D | Aeglea BioTherapeutics, Inc. AGLE | BAKER BROS. ADVISORS LP | 4,901,190 9.9% | 8,657 (+0.18%) | View |
| 2021-03-05 5:17 pm Unchanged | 13D | Aeglea BioTherapeutics, Inc. AGLE | BAKER BROS. ADVISORS LP | 4,892,533 9.9% | 0 (Unchanged) | View |
| 2021-02-16 4:53 pm Purchase | 13G | Aeglea BioTherapeutics, Inc. AGLE | BAKER BROS. ADVISORS LP | 4,892,533 9.9% | 3,178,929 (+185.51%) | View |
| 2021-02-16 3:14 pm Purchase | 13G | Aeglea BioTherapeutics, Inc. AGLE | Point72 Asset Management, L.P. | 2,929,787 6.1% | 41,811 (+1.45%) | View |
| 2021-02-16 10:21 am Sale | 13G | Aeglea BioTherapeutics, Inc. AGLE | Nantahala Capital Management, LLC | 2,414,002 4.9% | -438,258 (-15.37%) | View |
| 2021-02-12 4:59 pm Sale | 13G | Aeglea BioTherapeutics, Inc. AGLE | Lilly Ventures Fund I LLC | 2,568,543 5.4% | -80,666 (-3.04%) | View |
| 2021-02-12 4:39 pm Purchase | 13G | Aeglea BioTherapeutics, Inc. AGLE | ORBIMED ADVISORS LLC | 5,015,524 10.25% | 2,150,000 (+75.03%) | View |